| Improved survival in multiple myeloma and the impact of novel therapies SK Kumar, SV Rajkumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, ... Blood, The Journal of the American Society of Hematology 111 (5), 2516-2520, 2008 | 2878 | 2008 |
| Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients SK Kumar, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, S Pandey, ... Leukemia 28 (5), 1122-1128, 2014 | 1583 | 2014 |
| Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements S Kumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, C Colby, ... Journal of Clinical Oncology 30 (9), 989-995, 2012 | 1184 | 2012 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 JR Mikhael, D Dingli, V Roy, CB Reeder, FK Buadi, SR Hayman, ... Mayo Clinic Proceedings 88 (4), 360-376, 2013 | 715 | 2013 |
| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 649 | 2019 |
| Genetic progression and the waiting time to cancer N Beerenwinkel, T Antal, D Dingli, A Traulsen, KW Kinzler, VE Velculescu, ... PLoS computational biology 3 (11), e225, 2007 | 506 | 2007 |
| Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma MQ Lacy, SR Hayman, MA Gertz, A Dispenzieri, F Buadi, S Kumar, ... Journal of Clinical Oncology 27 (30), 5008-5014, 2009 | 432 | 2009 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines SK Kumar, JR Mikhael, FK Buadi, D Dingli, A Dispenzieri, R Fonseca, ... Mayo Clinic Proceedings 84 (12), 1095-1110, 2009 | 415 | 2009 |
| Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter D Dingli, KW Peng, ME Harvey, PR Greipp, MK O'Connor, R Cattaneo, ... Blood 103 (5), 1641-1646, 2004 | 387 | 2004 |
| Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics S Kumar, R Fonseca, RP Ketterling, A Dispenzieri, MQ Lacy, MA Gertz, ... Blood, The Journal of the American Society of Hematology 119 (9), 2100-2105, 2012 | 342 | 2012 |
| Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death E Muchtar, MA Gertz, SK Kumar, MQ Lacy, D Dingli, FK Buadi, M Grogan, ... Blood, The Journal of the American Society of Hematology 129 (15), 2111-2119, 2017 | 319 | 2017 |
| Remission of disseminated cancer after systemic oncolytic virotherapy SJ Russell, MJ Federspiel, KW Peng, C Tong, D Dingli, WG Morice, ... Mayo Clinic proceedings 89 (7), 926-933, 2014 | 310 | 2014 |
| Successful therapy must eradicate cancer stem cells D Dingli, F Michor Stem cells 24 (12), 2603-2610, 2006 | 310 | 2006 |
| Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease MQ Lacy, JB Allred, MA Gertz, SR Hayman, KD Short, F Buadi, ... Blood, The Journal of the American Society of Hematology 118 (11), 2970-2975, 2011 | 305 | 2011 |
| Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma MQ Lacy, A Dispenzieri, MA Gertz, PR Greipp, KL Gollbach, SR Hayman, ... Mayo Clinic Proceedings 81 (8), 1047-1053, 2006 | 303 | 2006 |
| A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy AK Stewart, PL Bergsagel, PR Greipp, A Dispenzieri, MA Gertz, ... Leukemia 21 (3), 529-534, 2007 | 286 | 2007 |
| Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma GS Nowakowski, TE Witzig, D Dingli, MJ Tracz, MA Gertz, MQ Lacy, ... Blood 106 (7), 2276-2279, 2005 | 274 | 2005 |
| Systemic amyloidosis from A (AA) to T (ATTR): a review E Muchtar, A Dispenzieri, H Magen, M Grogan, M Mauermann, ... Journal of internal medicine 289 (3), 268-292, 2021 | 266 | 2021 |
| Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria A Lakshman, SV Rajkumar, FK Buadi, M Binder, MA Gertz, MQ Lacy, ... Blood cancer journal 8 (6), 59, 2018 | 264 | 2018 |
| Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis TV Kourelis, SK Kumar, MA Gertz, MQ Lacy, FK Buadi, SR Hayman, ... Journal of clinical oncology 31 (34), 4319-4324, 2013 | 251 | 2013 |
